Anti-CD19 Anti-BCMA CAR-T cell therapy(Suzhou Maximum Biotech)

N/A

Report date: 2023/01/07 10:59:45

Base Information

Drug NameAnti-CD19 Anti-BCMA CAR-T cell therapy(Suzhou Maximum Biotech)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD19 +[4]

TargetsB-lymphocyte antigen CD19B-cell maturation protein

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesT-Maximum Pharmaceutical (Suzhou) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesT-Maximum Pharmaceutical (Suzhou) Co Ltd

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A